Cisplatin, arabinofuranosyl cytosine, and caffeine before radiation for glioblastomas

Benoit, Brien; Hugenholtz, Herman; Maroun, J.; Russell, Neville; Richard, Marie-Claude; Peterson, Eric W.; Dennery, Jean; Nabwangu, James F.; Grahovac, Zvonimir; Bélanger, Garry; Assang, Wanda; Hopkins, Harry S.; Girard, A.

doi:10.1007/978-1-4613-2297-9_52

Cited by 5 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the survival rate was not significantly improved in several clinical trials and cases. A group of patients with ependymoma were treated with cetuximab, carmustine, and bevacizumab intra-arterially, with the treatment being successful [ 57 ]. GBM patients were treated with intra-arterial drug delivery in several clinical studies.…”

Section: Methods Of Drug Deliverymentioning

confidence: 99%

Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors

et al. 2022

View full text Add to dashboard Cite

Chemotherapy as an adjuvant therapy that has largely failed to significantly improve outcomes for aggressive brain tumors; some reasons include a weak blood brain barrier penetration and tumor heterogeneity. Recently, there has been interest in designing effective ways to deliver chemotherapy to the tumor. In this review, we discuss the mechanisms of focused chemotherapies that are currently under investigation. Nanoparticle delivery demonstrates both a superior permeability and retention. However, thus far, it has not demonstrated a therapeutic efficacy for brain tumors. Convection-enhanced delivery is an invasive, yet versatile method, which appears to have the greatest potential. Other vehicles, such as angiopep-2 decorated gold nanoparticles, polyamidoamine dendrimers, and lipid nanostructures have demonstrated efficacy through sustained release of focused chemotherapy and have either improved cell death or survival in humans or animal models. Finally, focused ultrasound is a safe and effective way to disrupt the blood brain barrier and augment other delivery methods. Clinical trials are currently underway to study the safety and efficacy of these methods in combination with standard of care.

show abstract

Section: Methods Of Drug Deliverymentioning

confidence: 99%

Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

Kelsen

Hudis

Niedzwiecki

et al. 1991

Cancer

View full text Add to dashboard Cite

Conventional chemotherapy for unresectable or metastatic adenocarcinoma of the pancreas has had little effect on palliation or survival. Almost all studies of systemic therapy have involved empiric use of a variety of Phase II or conventional agents alone or in combination. On the basis of recent studies using a human tumor pancreatic cancer (PC) xenograft in nude mice, a Phase I clinical trial of cisplatin, high‐dose cytosine arabinoside (Ara‐C), and caffeine (CAC) was performed in patients with advanced incurable PC. A tolerable dose and schedule of the three agents were developed. Seven of 18 patients with measurable disease in this Phase I trial had partial responses to CAC. A Phase III comparison of CAC versus standard treatment using streptozotocin, mitomycin, and 5‐fluorouracil (SMF) was performed. Eighty‐two patients with advanced PC were entered into this random assignment trial. The two treatment arms were well balanced for the usual prognostic factors. Although the acute (e.g., nausea and vomiting) toxicities of CAC were greater than those of SMF, both groups of patients tolerated treatment reasonably well. Ninety percent of patients were evaluable for response. Two patients (5.5%) on the CAC treatment arm (95% confidence interval [CI], 0% to 15%) and four patients (10.2%) on the SMF treatment arm (95% CI, 1% to 22%) had objective responses (partial response in measurable disease or improvement in evaluable disease). No complete remissions were observed. The 95% confidence limits of response for CAC and SMF overlapped. The median duration of survival for all patients on the SMF treatment arm was 10 months, although it was 5 months on the CAC treatment arm (P = 0.008). In this Phase III comparison, CAC was not superior to conventional therapy with SMF in terms of response and was inferior for survival. Neither regimen is effective treatment for advanced PC.

show abstract

Chemotherapy for malignant gliomas of the brain: a review of ten-years experience

et al. 1990

View full text Add to dashboard Cite

In recent years, there has been a great improvement in the knowledge of the biological aspects of malignant gliomas of the brain. Conversely, there has been an increase of interest in the multimodal treatment of these tumours. In this review, we have analyzed the results of the several reports which have appeared in the literature that deal with the chemotherapeutic treatment of malignant gliomas. Furthermore, some areas of biological investigation that could have an impact on pharmacological therapy are discussed.

show abstract

Cisplatin, arabinofuranosyl cytosine, and caffeine before radiation for glioblastomas

Cited by 5 publications

References 11 publications

Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors

Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

Chemotherapy for malignant gliomas of the brain: a review of ten-years experience

Contact Info

Product

Resources

About